Antiviral Agents

"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.

Descriptor ID	D000998
MeSH Number(s)	D27.505.954.122.388
Concept/Terms	Antiviral Agents Antiviral Agents Agents, Antiviral Antivirals Antiviral Drugs Drugs, Antiviral

Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Anti-Infective Agents [D27.505.954.122]
Antiviral Agents [D27.505.954.122.388]

Below are MeSH descriptors whose meaning is related to "Antiviral Agents".

Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.

Bar chart showing 203 publications over 30 distinct years, with a maximum of 17 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	4	0	4
1997	1	0	1
1998	2	1	3
1999	1	0	1
2000	3	0	3
2001	1	0	1
2002	4	2	6
2003	2	2	4
2004	3	0	3
2005	1	0	1
2006	1	3	4
2007	5	1	6
2008	2	1	3
2009	1	4	5
2010	4	5	9
2011	4	1	5
2012	7	3	10
2013	9	5	14
2014	6	2	8
2015	10	1	11
2016	7	7	14
2017	9	0	9
2018	6	2	8
2019	1	1	2
2020	6	7	13
2021	14	3	17
2022	1	14	15
2023	2	11	13
2024	2	4	6
2025	4	0	4

Below are the most recent publications written about "Antiviral Agents" by people in Profiles.

Zvornicanin SN, Shaqra AM, Flynn J, Carias Martinez H, Jia W, Moquin S, Dovala D, Bolon DN, Kurt Yilmaz N, Schiffer CA. Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50. mBio. 2025 May 14; 16(5):e0406824.

View in: PubMed
Phan T, Ribeiro RM, Edelstein GE, Boucau J, Uddin R, Marino C, Liew MY, Barry M, Choudhary MC, Tien D, Su K, Reynolds Z, Li Y, Sagar S, Vyas TD, Kawano Y, Sparks JA, Hammond SP, Wallace Z, Vyas JM, Li JZ, Siedner MJ, Barczak AK, Lemieux JE, Perelson AS. Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance. J Virol. 2025 Mar 18; 99(3):e0162324.

View in: PubMed
Wang Y, Fu Q, Sha S, Yoon S. Interferon inhibitors increase rAAV production in HEK293 cells. J Biotechnol. 2025 Mar; 399:9-18.

View in: PubMed
Azzolino VN, Shaqra AM, Ali A, Kurt Yilmaz N, Schiffer CA. Structural Analysis of Inhibitor Binding to Enterovirus-D68 3C Protease. Viruses. 2025 Jan 08; 17(1).

View in: PubMed
Bennett FJ, Keilson JM, Turgeon MK, Oppat KM, Warren EAK, Shah SA, Agopian VG, Magliocca JF, Cameron A, Orloff SL, Kubal CA, Cannon RM, Akoad ME, Emamaullee J, Aucejo F, Vagefi PA, Nguyen MH, Dhanireddy K, Kazimi MM, Sonnenday CJ, Foley DP, Abdouljoud M, Sudan DL, Humar A, Doyle MBM, Chapman WC, Maithel SK. Racial Disparities in Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma. Ann Surg Oncol. 2025 Jan; 32(1):426-437.

View in: PubMed
Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, Laverdure S, Highbarger H, Lallemand P, Huang ML, Jerome KR, Sampoleo R, Mills MG, Greninger AL, Juneja K, Porter D, Benson CA, Dempsey W, El Sahly HM, Focht C, Jilg N, Paules CI, Rapaka RR, Uyeki TM, Clifford Lane H, Beigel J, Dodd LE. SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir. J Infect Dis. 2024 Sep 23; 230(3):624-634.

View in: PubMed
Azzolino VN, Shaqra AM, Ali A, Kurt Yilmaz N, Schiffer CA. Elucidating the Substrate Envelope of Enterovirus 68-3C Protease: Structural Basis of Specificity and Potential Resistance. Viruses. 2024 09 05; 16(9).

View in: PubMed
Tamura TJ, Choudhary MC, Deo R, Yousuf F, Gomez AN, Edelstein GE, Boucau J, Glover OT, Barry M, Gilbert RF, Reynolds Z, Li Y, Tien D, Vyas TD, Passell E, Su K, Drapkin S, Abar EG, Kawano Y, Sparks JA, Wallace ZS, Vyas JM, Shafer RW, Siedner MJ, Barczak AK, Lemieux JE, Li JZ. Emerging SARS-CoV-2 Resistance After Antiviral Treatment. JAMA Netw Open. 2024 09 03; 7(9):e2435431.

View in: PubMed
Geng LN, Bonilla H, Hedlin H, Jacobson KB, Tian L, Jagannathan P, Yang PC, Subramanian AK, Liang JW, Shen S, Deng Y, Shaw BJ, Botzheim B, Desai M, Pathak D, Jazayeri Y, Thai D, O'Donnell A, Mohaptra S, Leang Z, Reynolds GZM, Brooks EF, Bhatt AS, Shafer RW, Miglis MG, Quach T, Tiwari A, Banerjee A, Lopez RN, De Jesus M, Charnas LR, Utz PJ, Singh U. Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial. JAMA Intern Med. 2024 Sep 01; 184(9):1024-1034.

View in: PubMed
Bianchet E, de Gijsel D, Del Toro-Mejias LM, Stopka TJ, Hoskinson RA, Dowd P, Friedmann PD. More than Just Buying a Van: Lessons Learned from a Mobile Telehealth HCV Testing and Treatment Study. Viruses. 2024 08 30; 16(9).

View in: PubMed

People

Explore

Similar Concepts

Top Journals